1-3 of 3
Natalie E. Simpson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma

Andrea C. Baines, Rachel Ershler, Bindu Kanapuru, Qing Xu, Guoxiang Shen, Liang Li, Lian Ma, Olanrewaju O. Okusanya, Natalie E. Simpson, Wanda Nguyen, Marc R. Theoret, Richard Pazdur, Nicole J. Gormley
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (21): 4629–4633.
https://doi.org/10.1158/1078-0432.CCR-22-0618
Published: 01 November 2022
View article titled, FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma
Open the PDF for FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma in another window
Journal Articles

FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Emily Y. Jen, Xin Gao, Liang Li, Luning Zhuang, Natalie E. Simpson, Baikuntha Aryal, Rong Wang, Donna Przepiorka, Yuan Li Shen, Ruby Leong, Chao Liu, Christopher M. Sheth, Steven Bowen, Kirsten B. Goldberg, Ann T. Farrell, Gideon M. Blumenthal, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (3): 532–536.
https://doi.org/10.1158/1078-0432.CCR-19-2329
Published: 03 February 2020
View article titled, FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Open the PDF for FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in another window
Includes: Supplementary data
Journal Articles

Nonclinical Evaluations of Small-Molecule Oncology Drugs: Integration into Clinical Dose Optimization and Toxicity Management

Donna M. Dambach, Natalie E. Simpson, Thomas W. Jones, Richard J. Brennan, Richard Pazdur, Todd R. Palmby
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (11): 2618–2622.
https://doi.org/10.1158/1078-0432.CCR-15-2645
Published: 31 May 2016
View article titled, Nonclinical Evaluations of Small-Molecule Oncology Drugs: Integration into Clinical Dose Optimization and Toxicity Management
Open the PDF for Nonclinical Evaluations of Small-Molecule Oncology Drugs: Integration into Clinical Dose Optimization and Toxicity Management in another window